Potassium Channel Activators in Vascular Smooth Muscle

  • Robert H. Cox
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 308)


Ion channels play an important role in the function of all cells. They are involved in the determination of resting membrane potential, intracellular ion levels, action potential generation, and stimulus-response coupling. Over the last ten years, interest in ion channels as targets for therapeutic drug development has steadily increased. The Na+ channel was the first recognized as the site of action of therapeutically important compounds such as the local anesthetics. Over the last decade, Ca2+ channels have been the prominent site for the development of new modulatory agents. This activity has witnessed the development of numerous compounds with varying tissue specificity that modulate Ca2+ channel function. More recently, K+ channels have also become an important site of interest for the development of new therapeutic compounds (1). While K+ channel blockers have been available for many years, compounds that appear to function as K+ channel activators have been synthesized only recently.


Rest Membrane Potential Tail Artery Potassium Channel Activator Rabbit Portal Vein Rabbit Thoracic Aorta 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cook NS, Quast U, Hof RP, Baumlin Y, Pally C. Similarities in the mechanisms of action of two new vasodilator drugs: pinacidil and BRL 34915. J Cardiovasc Pharmacol 11: 90, 1988.PubMedCrossRefGoogle Scholar
  2. 2.
    Jones AW. Content and fluxes of electrolytes. Handbook of Physiology, The Cardiovascular System, VII, Vascular Smooth Muscle, Bethesda: American Physiological Society, 1980, p 253.Google Scholar
  3. 3.
    Stekiel W. Electrophysiological mechanisms of force development by vascular smooth muscle membrane in hypertension. In: Blood Vessel Changes in Hypertension: Structure and Function, VII, R.M.K.W. Lee (ed). Boca Raton: CRC Press, pp 127, 1989.Google Scholar
  4. 4.
    Buckingham RE, Clapham JC, Hamilton TC, Longman SD, Nortaon J, Poyser RH. BRL 34915, a novel antihypertensive agent: Comparison of effects on blood pressure and other hemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol 8: 798, 1986.PubMedGoogle Scholar
  5. 5.
    Buckingham RE, Hamilton TC, Howlett DR, Mootoo S, Wilson C. Inhibition by glibenclamide of the vasorelaxant action of cromakalim in the rat. Br J Pharmacol 97: 57, 1989.PubMedGoogle Scholar
  6. 6.
    Cavero I, Mondot S, Mestre M. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels. J Pharmacol Exp Ther 248: 1261, 1989.PubMedGoogle Scholar
  7. 7.
    Hof RP, Quast U, Cook NS, Blarer S. Mechanism of action and systemic and regional hemodynamics of the potassium channel activator BRL34915 and its enantiomers. Circ Res 62: 679, 1988.PubMedGoogle Scholar
  8. 8.
    Quast U, Cook NS. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. J Pharmacol Exp Ther 250: 261, 1989.Google Scholar
  9. 9.
    VandenBerg MJ, Woodward SR, Hossain M, Stewart-Long P, Tasker TCG. Potassium channel activators lower blood pressure: an initial study of BRL 34915 in hypertensive patients. J Hypertension 4: S166, 1986Google Scholar
  10. 10.
    Hamilton TC, Weir SW, Weston AH. Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol 88: 103, 1986.PubMedGoogle Scholar
  11. 11.
    Shetty SS, Weiss GB. Dissociation of actions of BRL 34915 in the rat portal vein. Eur J Pharmacol 141: 485, 1987.PubMedCrossRefGoogle Scholar
  12. 12.
    Weir SW, Weston AH. Effect of apamin on responses to BRL 34925, nicorandil and other relaxants in the guinea-pig taenia caeci. Br J Pharamcol 88: 113, 1986.Google Scholar
  13. 13.
    Cook NS. The pharmacology of potassium channels and their therapeutic potential. TIPS 9: 21, 1988.PubMedGoogle Scholar
  14. 14.
    Quast U. Effects of the K+ efflux stimulating vasodilator BRL 34915 on S6Rb+ efflux and spontaneous activity in guinea-pig portal vein. Br J Pharmacol 91: 569, 1987.PubMedGoogle Scholar
  15. 15.
    Allen SL, Boyle JP, Cortijo J, Foster RW, Morgan GP, Small RC. Electrical and mechanical effects of BRL34915 in guinea-pig isolated trachealis. Br J Pharmacol 89: 395, 1986.PubMedGoogle Scholar
  16. 16.
    Kuromaru O, Sakai K. Effects of nicorandil on the rhythmic contractile response of isolated miniature pig coronary artery to 3,4diaminopyridine: Comparison with nitroglycerin. Arch Int Pharmacol Therap 283: 272, 1986.Google Scholar
  17. 17.
    Weir SW, Weston AH. The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels. Br J Pharmacol 88: 121, 1986.PubMedGoogle Scholar
  18. 18.
    Clapham JC, Wilson C. Anti-spasmogenic and spasmolytic effects of BRL 34915: a comparison with nifedipine and nicorandil. J Auton Pharmacol 7: 233, 1987.PubMedCrossRefGoogle Scholar
  19. 19.
    Wilson C, Coldwell MC, Howlett DR, Cooper SM, Hamilton TC. Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil. Eur J Pharmacol 152: 331, 1988.PubMedCrossRefGoogle Scholar
  20. 20.
    Cox RH. Effects of putative K+ channel activator BRL-34915 on arterial contraction and 86Rb efflux. J Pharmacol Exp Ther 252: 51, 1990.PubMedGoogle Scholar
  21. 21.
    Scholtysik G. Evidence for inhibition by ICS 205–930 and stimulation by BRL 34915 of K+ conductance in cardiac muscle. Naun-Schmied Arch Pharmacol 335: 692, 1987.CrossRefGoogle Scholar
  22. 22.
    Gotanda K, Satoh K, Taira N. Is the cardiovascular profile of BRL 34915 characteristic of potassium channel activators? J Cardiovasc Pharmacol 12: 239, 1988.PubMedCrossRefGoogle Scholar
  23. 23.
    Kerr MJ, Wilson R, Shanks RG. Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug. J Cardiovasc Pharmacol 7: 875, 1985.PubMedCrossRefGoogle Scholar
  24. 24.
    Grover GJ, McCullough JR, Henry DE, Condor ML, Sleph PG. Antiischemic effects of the potassium channel activators pinacidil and cromakalim, and the reversal of these effects with the potassium channel blocker glyburide. J Pharmacol Exp Ther 251: 98, 1989.PubMedGoogle Scholar
  25. 25.
    Coldwell MC, Howlett DR. Specificity of action of the novel antihypertensive agent, BRL 34915, as a potassium channel activator. Biochem Pharmacol 36: 3663, 1987.PubMedCrossRefGoogle Scholar
  26. 26.
    Quast U, Baumlin Y. Comparison of the effluxes of 42K+ and 86Rb+ elicited by cromakalim (BRL 34915) in tonic and phasic vascular tissue. Naun-Schmied Arch Pharmacol 338: 319, 1988.Google Scholar
  27. 27.
    Post JM, Smith JM, Jones AW. BRL 34925 (cromakalim) stimulation of 42K efflux from rabbit arteries is modulated by calcium J Pharmacol Exp Ther 250: 591, 1989.PubMedGoogle Scholar
  28. 28.
    Latorre R, Miller C. Conduction and selectivity in potassium channels. J Membr Biol 71: 11, 1983.PubMedCrossRefGoogle Scholar
  29. 29.
    Yamanaka K, Furukawa K, Kitamura K. The different mechanisms of action of nicorandil and adenosine triphosphate on potassium channels of circular smooth muscle of the guinea-pig small intestine. Naun-Schmied Arch Pharmacol 331: 96, 1985.CrossRefGoogle Scholar
  30. 30.
    Beech DJ, TB Bolton. Effects of BRL 34915 on membrane currents recorded from single smooth muscle cells from the rabbit portal vein. Br J Pharmacol 92: 550P, 1987.Google Scholar
  31. 31.
    Standen NB, Quayle JM, Davies NW, Brayden JE, Huang Y, Nelson MT. Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science 245: 177, 1989.PubMedCrossRefGoogle Scholar
  32. 32.
    Iijima T, Taira N. Pinacidil increases the background potassium current in single ventricular cells. Eur J Pharmacol 141: 139, 1987.PubMedCrossRefGoogle Scholar
  33. 33.
    Arena JP, Kass RS. Enhancement of potassium-sensitive current in heart cell by pinacidil. Evidence for modulation of the ATP-sensitive potassium channel. Circ Res 65: 4366, 1989.Google Scholar
  34. 34.
    Winquist RJ, Henry LA, Wallace AA, Baskin EP, Stein RB, Garcia ML, Kaczorowski GJ. Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle. J Pharmacol Exp Ther 248: 149, 1989.PubMedGoogle Scholar
  35. 35.
    Hollingsworth M, Amedee T, Edwards D, Mironneau J, Savineau JP, Small RC, Weston AH. The relaxant effect of BRL 34915 in rat uterus. Br J Pharmacol 91: 803, 1987.PubMedGoogle Scholar
  36. 36.
    Cook DL, CN Hales CN. Intracellular ATP directly blocks K+ channels in pancreatic cells. Nature (Lond) 311: 271, 1984.Google Scholar
  37. 37.
    Sturgess NC, Ashford MLJ, Cook DL, Hales CN. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 2: 474, 1985.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Robert H. Cox
    • 1
    • 2
  1. 1.Bockus Research InstituteThe Graduate HospitalPhiladelphiaUSA
  2. 2.Department of PhysiologyThe University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations